Report Overview

The Canada Peptic Ulcers Drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. A peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. In 2019, around 1.3 out of 100,000 Canadians died from peptic ulcers.Furthermore, an increase in the patient pool and the rise in consumption of drugs such as aspirin, ibuprofen, and other inflammatory drugs are the other factors anticipated to augment the global peptic ulcer market from 2019 to 2028.



Market Drivers

The major driving factors for the peptic ulcer drug market are stress, drug-induced ulcers, the growing rate of infection, changes in food, rise in cancer, tobacco, alcohol use, and the ever-increasing geriatric population. The demand for these ulcer drugs is experiencing considerable growth as major pharmaceutical companies are increasing their focus on R&D activities to develop new medicines and cater to the need for OTC drugs across several stores. The increasing prevalence of peptic ulcer disease is driving the demand for effective peptic ulcer drugs. The market is, therefore, expected to showcase positive growth during the forecast period.